Abstract

IntroductionBladder cancer ranks the first in the morbidity of urogenital malignancies in China. Bladder cancers are pathologically classified into 2 sub-types, including non-muscle invasion bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC). MIBC is a highly lethal tumor and targeted therapies showed promising prospect for the treatment of MIBC. Novel therapeutic targets are still badly needed to combat this disease. The kinesin family member 14 (KIF14) is an engaging molecular motor and involved in multiple cellular processes such as cell division. Additionally, KIF14 is highly expressed in multiple tumor tissues and participates in the progression of several cancers such as gastric cancer and hepatocellular carcinoma. However, its possible role in the development of bladder cancer remains unclear.Material and methodsHerein, 107 cases of MIBC tissue specimens were collected and detected by immunohistochemistry assays, and we analyzed the relationship between AKIF14 expression and clinical features. Then we used the cell line T24 and 5637 of bladder cancer into the experimental group transfected shKIF14 plasmid.KIF14, additionally, fascinated tumor growth of MIBC in mice.ResultsWe demonstrated the high expression of KIF14 in tumor tissues from patients who underwent MIBC. Furthermore, KIF14 was statistically correlated with clinical feature, such as tumor stage (P = 0.001). Our results further confirmed the impairment of proliferation capacity after KIF14 ablation in vitro and in vivo.ConclusionsIn summary, we revealed KIF14 could serve as a promising therapeutic target for the treatment of MIBC.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.